Lexicon's 30-Year Gene Hack: 5,000 Mouse Knockouts, 80 Trial Crashes, Just 2 FDA Deploys

Lexicon Pharmaceuticals, Inc. (LXRX) presented at the 44th Annual J.P. Morgan Healthcare Conference, held on January 15, 2026, at 3:00 PM EST, where CEO Michael Exton and Senior VP & Chief Medical Officer Craig Granowitz shared the company's story and progress. The conference, hosted by JPMorgan, provided a platform for Lexicon to showcase its achievements, including the approval of two medicines in the United States and the development of new novel mechanisms, such as a non-opioid approach for neuropathic pain and a non-incretin mechanism for obesity. Founded 30 years ago, Lexicon has a rich history of innovation, having created knockout mouse lines for 5,000 genes and identifying 200 genes of interest, which has led to over 80 clinical trials and the approval of medicines like INPEFA. As Exton noted, the company's bold plan to take on the human genome has resulted in significant advancements, with the company now focusing on commercialization and further research. With a strong leadership team, including Exton, Granowitz, and Chief Financial Officer Scott, Lexicon is poised to continue making strides in the pharmaceutical industry, with its presentation at the J.P. Morgan Healthcare Conference serving as a testament to its commitment to innovation and progress.